4D Pharma plc, a pharmaceutical company specializing in the development of live biotherapeutic products – a novel class of drug derived from the microbiome – has completed its merger with Longevity Acquisition Corporation. 4D pharma American Depositary Shares are expected to begin trading today on the Nasdaq Global Market under the ticker symbol ‘LBPS.’
Warrants of Longevity assumed by 4D pharma in the Merger are currently expected to begin trading on Nasdaq under the ticker symbol ‘LBPSW’, on March 23. Longevity units are expected to be separated and holders thereof are expected receive 4D pharma ADSs and warrants in exchange at the same time as the warrants begin trading.
As a result of the Merger, Longevity shares, warrants, rights and units ceased trading on Nasdaq on Friday, March 19, 2021. 4D pharma ordinary shares continue to be admitted to trading on the London Stock Exchange’s AIM market under the ticker symbol ‘DDDD.’